Caplin Point Laboratories (CAPLIPOINT) Share Price Falls 2.77% Today

Caplin Point Laboratories Share Price fell to Rs 2,764 on 04 September 2026, down 2.77% for the day, taking the company’s market capitalisation to Rs 20,634.9 crore. The Large Cap pharmaceutical stock opened at Rs 2,867.1 and moved lower through the session, with today’s decline drawing attention because the stock slipped from a previous close of Rs 2,842.8 to its intraday low of Rs 2,764.

For investors tracking Caplin Point Laboratories Share Price Today and broader stock market moves, the supplied data confirms the price event but does not establish a company-specific catalyst behind the fall. What is clear is that the stock is trending because of a notable single-day decline, while the company’s valuation and profitability profile remain important to the discussion. At the current price, the stock trades at a P/E ratio of 51.48 and a P/B ratio of 9.95, with ROE at 21.36% and ROCE at 27.07%. On Univest, this makes the stock relevant not only for today’s price action but also for its premium positioning within the Healthcare and Pharmaceuticals & Drugs segment.

Caplin Point Laboratories (CAPLIPOINT) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,764
Previous Close	Rs 2,842.8
Today's Move	-Rs 78.80 (-2.77%)
Open	Rs 2,867.1
High	Rs 2,867.1
Low	Rs 2,764
Turnover	Rs 1.49 crore
Market Capitalisation	Rs 20,634.9 crore
Market Cap Category	Large Cap

Caplin Point Laboratories Share Price Today reflects a clear intraday decline, with the stock opening at Rs 2,867.1 against the previous close of Rs 2,842.8 and then moving down to Rs 2,764. The day high also stood at Rs 2,867.1, which means the opening level was the session’s peak, while the day low matched the current traded price in the supplied data.

That pattern shows that the early level could not be sustained and that the stock weakened through the morning trade. The absolute decline of Rs 78.8 translates into a 2.77% fall for the day. Turnover stood at Rs 1.49 crore at the time captured by the data, indicating the stock was active enough to attract near-term market attention. As a Large Cap name with a market cap of Rs 20,634.9 crore, Caplin Point Laboratories Share Price News matters beyond a purely small-cap trading move because it sits within an established listed pharmaceutical company. From here, investors usually shift from price action to whether the valuation and profitability profile still supports close tracking on Univest.

Caplin Point Laboratories (CAPLIPOINT) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 20,634.9 crore
P/E Ratio	51.48x
P/B Ratio	9.95x
ROE	21.36%
ROCE	27.07%
EPS	Rs 55.22
Book Value Per Share	Rs 285.6
Dividend Yield	0.28%

Caplin Point Laboratories Fundamental Analysis remains central because today’s decline comes in a company that still shows strong profitability ratios. The stock’s market capitalisation stands at Rs 20,634.9 crore, and at the current price it trades at a P/E ratio of 51.48 and a P/B ratio of 9.95. These are valuation multiples, and both become more meaningful when read alongside returns.

On profitability, ROE is 21.36% and ROCE is 27.07%, both comfortably in double digits and indicative of a business that has generated healthy returns on shareholder equity and capital employed. EPS stands at 55.22, which represents earnings attributable to each share. Book value per share is Rs 285.6, showing the accounting net worth behind each share. Dividend yield is 0.28, which points to a modest historical payout relative to the current stock price.

In plain terms, Caplin Point Laboratories Share Price is seeing a day-specific decline even though the supplied company financial markers are not weak in isolation. That is why the stock remains part of active stock analysis on Univest: the key question is not just that the share price fell, but whether premium valuation continues to be supported by the quality of returns and its industry positioning.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	51.48x
Benchmark Median P/E	32.61x
Benchmark Average P/E	48.83x
Benchmark P/E Range	3.32x to 645.91x
Company P/B Ratio	9.95x
Benchmark Median P/B	2.89x
Benchmark Average P/B	4.31x
Company ROE	21.36%
Benchmark Median ROE	11.79%
Benchmark Average ROE	11.17%
Company ROCE	27.07%
Benchmark Median ROCE	13.66%
Benchmark Average ROCE	13.7%
Company Market Capitalisation	Rs 20,634.9 crore
Benchmark Median Market Cap	Rs 730.27 crore
Benchmark Average Market Cap	Rs 14,155.46 crore

Caplin Point Laboratories operates in Healthcare within the Pharmaceuticals & Drugs industry, and the benchmark data gives useful context for today’s move. Against 201 companies in the same industry, the stock’s valuation sits above the median on both earnings and book value multiples, while its return ratios are also stronger than broad industry norms.

The sector snapshot shows Caplin Point Laboratories Share Price is attached to a company P/E of 51.48. That compares with an industry median P/E of 32.61 and an average of 48.83 across 169 companies, within a wide range of 3.32 to 645.91. On P/B, the company stands at 9.95 versus a median of 2.89 and an average of 4.31 across 200 companies, with the broader range running from -11.14 to 27.89.

Returns tell a different story from valuation. Company ROE of 21.36% is well above the industry median of 11.79% and average of 11.17. Company ROCE of 27.07% is also materially higher than the median of 13.66% and average of 13.7. In market-cap terms, Caplin Point Laboratories at Rs 20,634.9 crore is bigger than the industry median of Rs 730.27 crore and above the average of Rs 14,155.46 crore, though still far below the largest player at Rs 4,63,791.45 crore. On Univest, that combination suggests a business priced at a premium but backed by stronger-than-average sector returns.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,63,791.45	37.77	5.28	14.85	19.11
Divi's Laboratories	DIVISLAB	2,45,080.59	83.91	13.89	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,90,351.29	85.89	20.87	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,14,832.64	25.09	4.2	19.69	21.39
Cipla	CIPLA	1,14,162.52	33.29	3.19	11.83	16

Peer data shows why Caplin Point Laboratories Share Price continues to command attention despite today’s decline. Its P/E of 51.48 is higher than Sun Pharmaceutical Industries at 37.77, Zydus Lifesciences at 25.09 and Cipla at 33.29, but lower than Divi’s Laboratories at 83.91 and Torrent Pharmaceuticals at 85.89. That places the stock in the upper valuation band, though not at the most expensive end among major pharmaceutical peers.

On P/B, Caplin Point stands at 9.95, above Sun Pharma’s 5.28, Zydus’s 4.2 and Cipla’s 3.19, but below Divi’s 13.89 and Torrent’s 20.87. Profitability is comparatively solid: ROE of 21.36% is ahead of Sun Pharma, Divi’s, Zydus and Cipla, though below Torrent’s 26.76%. ROCE of 27.07% is stronger than Sun Pharma, Divi’s, Torrent and Cipla, and above Zydus as well. Market cap remains smaller than each of these peers, with the company at Rs 20,634.9 crore versus peer figures above Rs 1,14,162.52 crore in the supplied list. That creates an interesting profile in which the company combines smaller scale with relatively strong returns and a premium valuation.

Why Investors Are Watching Caplin Point Laboratories

• The stock fell 2.77% today, with the price dropping Rs 78.8 from the previous close.
• Intraday price action was weak, as the opening level of Rs 2,867.1 also marked the day’s high.
• Valuation remains elevated at 51.48 times earnings and 9.95 times book value.
• Profitability metrics are strong, with ROE at 21.36% and ROCE at 27.07%.
• Industry comparisons show returns above benchmark averages, even as valuation sits at a premium.

About Caplin Point Laboratories

Caplin Point Laboratories is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company is a listed pharmaceutical business within one of India’s most closely tracked healthcare segments. Its market capitalisation of Rs 20,634.9 crore places it in the Large Cap category, which gives the stock a different profile from smaller drug makers that may see sharp price swings with less institutional attention. For readers following Caplin Point Laboratories Stock News, the company sits in an industry where valuation, return ratios and peer comparisons are all closely watched.

Track Caplin Point Laboratories Share Price on Univest

UseCaplin Point Laboratories (CAPLIPOINT) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can track Caplin Point Laboratories Share Price with live price updates, 52-week level references when available, key fundamental ratios, shareholding pattern data when disclosed, and broader market insights. Caplin Point Laboratories Share Price Today is best read alongside valuation multiples, sector benchmarks and peer comparisons, all of which help turn a simple price move into more informed stock analysis. Univest also helps users monitor daily price action in context rather than in isolation.

Frequently Asked Questions

Why is Caplin Point Laboratories Share Price falling today?

Ans. Caplin Point Laboratories Share Price is down 2.77% today at Rs 2,764 versus the previous close of Rs 2,842.8. The supplied data confirms the decline, but it does not establish a company-specific reason for the move.

What is Caplin Point Laboratories Share Price Today?

Ans. Caplin Point Laboratories Share Price Today is Rs 2,764. The stock has declined by Rs 78.8, or 2.77%, from the previous close of Rs 2,842.8, making it a notable price action move in today’s market session.

What does today’s price action show for Caplin Point Laboratories?

Ans. The stock opened at Rs 2,867.1, which also remained the day’s high, and then fell to Rs 2,764, the day’s low. That pattern indicates early weakness after the open and sustained pressure during the session.

Is Caplin Point Laboratories a large-cap stock?

Ans. Yes, Caplin Point Laboratories is classified as a Large Cap company in the supplied data. Its market capitalisation stands at Rs 20,634.9 crore, which gives it greater market relevance than a typical smaller pharmaceutical stock.

What valuation ratios are investors watching in Caplin Point Laboratories?

Ans. Investors are tracking a P/E ratio of 51.48 and a P/B ratio of 9.95. These are premium valuation levels relative to several peers and also above the industry median figures shown in the sector benchmark data.

How profitable is Caplin Point Laboratories based on the supplied data?

Ans. The company shows ROE of 21.36% and ROCE of 27.07%, both strong return indicators. EPS stands at 55.22, while book value per share is Rs 285.6, adding context to profitability and valuation discussions.

How does Caplin Point Laboratories compare with the pharmaceutical industry benchmark?

Ans. Its P/E of 51.48 is above the industry median of 32.61 and slightly above the average of 48.83. However, ROE of 21.36% and ROCE of 27.07% are both well above industry median and average levels.

How does Caplin Point Laboratories compare with major pharma peers?

Ans. Caplin Point Laboratories trades at a higher P/E than Sun Pharma, Zydus and Cipla, but below Divi’s and Torrent. Its ROCE of 27.07% is stronger than all five supplied peers in the comparison set.

Does Caplin Point Laboratories pay a dividend?

Ans. The supplied data shows a dividend yield of 0.28. That indicates a modest historical payout relative to the current stock price of Rs 2,764 and should be read as current data rather than a future assurance.

What should investors monitor next in Caplin Point Laboratories Stock News?

Ans. Investors may watch whether Caplin Point Laboratories Share Price stabilises after today’s fall, while also tracking its premium valuation, strong ROE and ROCE, and how it continues to compare with pharmaceutical sector benchmarks and peers.